Treatment of hepatic encephalopathy in patients with cirrhosis of the liver

Digestive Diseases

Volumn 14, Issue , 1996, Pages 40-52

  Ferenci, Peter ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Ammonia; Diet; False neurotransmitters; GABA benzodiazepine; Hepatic encephalopathy; Treatment; Zinc

Indexed keywords

4 AMINOBUTYRIC ACID; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; AMMONIA; BRANCHED CHAIN AMINO ACID; NITROGEN; PLACEBO;

CLINICAL TRIAL; DRUG ANTAGONISM; HEPATIC ENCEPHALOPATHY; HUMAN; INTESTINE; LIVER CIRRHOSIS; METABOLISM; METHODOLOGY; REVIEW; SAMPLE SIZE; URINE;

AMINO ACIDS, BRANCHED-CHAIN; AMMONIA; CLINICAL TRIALS; GAMMA-AMINOBUTYRIC ACID; HEPATIC ENCEPHALOPATHY; HUMANS; INTESTINES; LIVER CIRRHOSIS; NEUROTRANSMITTER AGENTS; NITROGEN; PLACEBOS; RESEARCH DESIGN; SAMPLE SIZE;

EID: 2742518053     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000171582     Document Type: Article

References (58)

1. Conn HO, Lieberthal MM: The Hepatic Coma Syndromes and Lactulose. Baltimore, Williams & Wilkins, 1979.
2. Conn HO, Leevy CM, Vlahcevic ZR, Rodgers JB, Maddrey WC, Secff L, Levy LL: Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. Gastroenterology 1977;72:573-583.
3. Schomerus H, Hamster W, Blunck H, Reinhard U, Mayer K, Dôlle W: Latent portosystemic encephalopathy. I. Nature of cerebral functional defects and fitness to drive. Dig Dis Sci 1981;26:622-630.
4. Rikkers L, Jenko P, Rudman D, Freides D: Subclinical hepatic encephalopathy: Detection, preva lence and relationship to nitrogen metabolism. Gastroenterology 1978;75:462-469.
5. Conn HO: Trailmaking and number connection tests in the assessment of mental state in portal systemic encephalopathy. Am J Dig Dis 1977; 22:541-550.
6. Elsass P, Christensen SE. Mortensen L, Vilstrup H: Discrimination between organic and hepatic encephalopathy by means of continuous reaction times. Liver 1985;5:29-34.
7. Kullmann F, Hollerbach S, Holstege A, Schôlmerich J: Subclinical hepatic encephalopathy: The diagnostic value of evoked potentials. J Hepatol 1995;22:101-110.
8. Fercnci P, Piispok A, Steindl P: Current concepts in the pathophysiology of hepatic encephalopathy. Eur J Clin Invest 1992;22:573-581.
9. Uribe M, Campollo O, Vargas F: Acidifying enemas (lactitol and lactulose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: A doubleblind randomized clinical trial. 1-Iepatology 1987;7:639-634.
10. Bockel R, DolToel M: Lavage digestif au mannitol dans les hémorragies digestives du cirrhotique. Nouv Press Méd 1981;10:33-36.
11. Bucci L, Palmieri GC: Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin 1993;13:109-118.
12. Tarao K, Ikeda T, Hayashi K, Saku-rai A, Okada T, Ito T, Karube H, Nomoto T, Mizumo T, Shindo K: Successful use of vancomycin hydrochloride in the treatment of lactulose-resistant chronic hepatic encephalopathy. Gut 1990:31:702-706.
13. Mortensen PB, Holtug K, Bonnen H, Clausen MR: The degradation of amino acids, proteins, and blood to short-chain fatty acids in colon is prevented by lactulose. Gastroenterology 1990;98:353-360.
14. Van Thiel DH, Fagiuoli S, Wright HI, Chien MC, Gavaler JS: Gastrointestinal transit in cirrhotic patients: Effect of hepatic encephalopathy and its treatment. Hepatology 1994;19:67-71.
15. Mortensen PB: The effect of oral administered lactulose on colonic nitrogen metabolism and excretion. Hepatology 1992;16:1350-1356.
16. Bircher J, Müller J, Guggenheim P, et al: Treatment of chronic portal-systemic encephalopathy with lactulose. Lancet 1966;i:890-893.
17. Orlandi F, Brunelli E, Benedetti A, Macarri G: Clinical trials of nonabsorbable disaccharide therapy in hepatic encephalopathy; in Conn HO, Bircher J (eds): Hepatic Encephalopathy. Syndromes and Therapies. Bloomington, Medi-Ed Press, 1994. pp 209-218.
18. Morgan MY, Hawley KE: Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: A double-blind, randomized trial. Hepatology 1987;7: 1278-1284.
19. Salerno F, Moser P, Maggi A, Vita-liani G, Benetti G: Effects of longterm administration of low-dose lactitol in patients with cirrhosis but without overt encephalopathy. J Hepatol 1994;21:1092-1096.
20. Uribe M, Marquez MA, Gargara-mos G, et al: Treatment of chronic portal systemic encephalopathy with lactose in lactase-deficient patients. Dig Dis Sci 1980;25:914- 928.
21. Loguercio C, Abbiati R, Rinaldi M, Romano A, del Vecchio Blanco C, Collori M: Long-term effects of En-lerococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy. J Hepatol 1995;23: 39-46.
22. Haussinger D: Nitrogen metabolism in liver: Structural and functional organization and physiologic relevance. Biochcm J 1990;267:281- 290.
23. Staedt U, Leweling H, Gladisch R, Kortsik C, Hagmullcr E, Holm E: Effects of omithine aspartate on plasma ammonia and plasma amino acids in patients with cirrhosis. A double-blind, randomized study using a four-fold crossover design. J Hepatol 1993;19:424-430.
24. Kircheis G, Quack G, Erbler H: L-Omithine-/.-aspartate in the treatment of hyperammonemia and hepatic encephalopathy; in Conn HO, Bircher J (eds): Hepatic Encephalopathy. Syndromes and Therapies. Bloomington, Medi-Ed Press, 1994, pp 373-383.
25. Mendenhall CL, Rousler S, Marshall L, Wcesner R: A new therapy for portal systemic encephalopathy. Am J Gastroenterol 1986;81:540-543.
26. Sushma S, Dasarathy S, Tandon RK, Jain S, Gupta S, Bhist MS: Sodium benzoate in the treatment of acute hepatic encephalopathy: A double-blind randomized trial. Hepatology 1992;16:138-144.
27. Fischer JE, Funovics J, Aguirre A: The role of plasma amino acid in hepatic encephalopathy. Surgery 1975;78:276-290.
28. Fcrenci P: Critical evaluation of the role of branched chain amino acids in liver disease; in Thomas JC, Jones EA (eds): Recent Advances in Hepatology. Edinburgh. Churchill Livingstone, 1986, pp 137-154.
29. Naylor CD, O'Rourkee K, Detsky AS, Baker JP: Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy. A metaanalysis. Gastroenterology 1989:97: 1033-1042.
30. Eriksson S, Conn HO: Branched-chain amino acids in hepatic encephalopathy (correspondence). Gastroenterology 1990;99:604-607.
31. Egberts EH, Shomerus H, Hamster W, Jürgens P: Branched chain amino acids in the treatment of latent portosystemic encephalopathy. Gastroenterology 1985;88:887-895.
32. Marchesini G, Dioguardi FS, Bian-chi GP, et al: Long-term branched chain amino acid treatment in chronic hepatic encephalopathy. J Hepatol 1991:11:92-101.
33. Horst D, Grace ND, Conn HO, et al: Comparison of dietary protein with an oral, branched chain-enriched amino acid supplement in chronic portal-systemic encephalopathy: A randomized controlled trial. Hepa-tology 1984:4:279-287.
34. Hcrlong GF, Maddrey WC, Walser M: The use of ornithine salts of branched chain ketoacids in portal systemic encephalopathy. Ann Intern Med 1980:93:545-550.
35. Michel H, Solere M, Grainer P: Treatment of cirrhotic hepatic encephalopathy with /.-dopa: A controlled trial. Gastroenterology 1980: 79:207-211.
36. Morgan M, Jakobovits AW, James M, Sherlock S: Successful use of bromocriptine in the treatment of hepatic encephalopathy. Gastroenterology 1980;78:663-670.
37. Uribe M, Farca A, Marquez MA, et al: Treatment of chronic portal systemic encephalopathy with bromocriptine. Gastroenterology 1979:76: 1347-1351.
38. Grimm G, Ferenci P, Katzenschla-gcr R, et al: Improvement of hepatic encephalopathy treated with fluma-zenil. Lancet 1988;ii: 1392-1394.
39. Bansky G, Meier PE, Riedercr E, et al: Effects of the benzodiazepine receptor antagonist flumazenil in hepatic encephalopathy in humans. Gastroenterology 1989:97:744-753.
40. Ferenci P, Grimm G, Meryn S, Gangl A: Successful Long-term treatment of portal systemic encephalopathy by the benzodiazepine antagonist flumazenil. Gastroenterology 1989:96:240-243.
41. Pomier-Layrargues JF, Gigubre J, Lavoie S, et al: Pharmacokinetics of benzodiazepine antagonist Ro 15-1788 in cirrhotic patients with moderate or severe liver dysfunction. Hepatology 1989:10:969-972.
42. Basile AS, Harrison PM, Hughes RD, et al: Relationship between plasma benzodiazepine receptor ligand concentrations and severity of hepatic encephalopathy. Hcpatolo-gy 1994:19:112-121.
43. Pomier-Layrargues JF, Giguerc J, Lavoie S, et al: Flumazenil in cirrhotic patients in hepatic coma: A randomized double-blind placebo-controlled crossover trial. Hepatology 1994;19:32-37.
44. Gyr N, et al: Synopsis of Research Report B-154. 321 (Protocol N-12725a). Basel. Hoffmann-La Roche, 1993.
45. Cadranel JF, El Younsi M, Pidoux B, et al: Immediate improvement of hepatic encephalopathy in cirrhotic patients by flumazenil. Results of a double-blind cross-over study. J Hepatol 1991; 13(suppl 2):S104.
46. Jones EA, Gammal SA, Hepatic encephalopathy: in Arias I, Jakoby WB, Popper H (eds): The Liver: Biology and Pathobiology. New York. Raven Press, 1988.
47. Van der Rijt CCD, Schalm SW, Meulstee J, Slijneu T: Flumazenil therapy for hepatic encephalopathy: A double-blind cross-over study. Hepatology 1989:10:590A.
48. Amodio P, Marchelti P, Comacchio F, et al: Effects of flumazenil on sub-clinical hepatic encephalopathy: Preliminary data. Ital J Gastroenterol 1993:25:183.
49. Van der Rijt CC, Schalm SW, Schat H, Foeken K, De Jong G: Overt hepatic encephalopathy precipitated by zinc deficiency. Gastroenterology 1991;100:1114-1148.
50. Halsted JA, Hackley B, Rudzsi C, Smith JC: Plasma zinc concentration in liver diseases. Comparison with normal controls and certain other chronic diseases. Gastroenterology 1968;54:1098-1105.
51. Zeneroli ML, Baraldi M: Neurotransmission in hepatic encephalopathy. Adv Exp Med Biol 1990;272: 135-148.
52. Reding P, Duchatcau J, Bataille C: Oral zinc supplementation improves hepatic encephalopathy. Results of a randomized controlled trial. Lancet 1984;ii:493-495.
53. Brcsci G, Parisi G, Banti S: Management of hepatic encephalopathy with oral zinc supplementation: A long-term treatment. Eur J Med 1993;2:414-416.
54. Riggio O, Ariosto F, Merli M, Cas-chera M, Zullo A, Balducci G, Zipa-ro V, Pedretti G, Fiaccadori F, Bot-tari E, et al: Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy. Results of a double-blind crossover trial. Dig Dis Sci 1991:36:1204-1208.
55. Uribe M, Marquez MA, Ramos GG, et al: Treatment of chronic portal-systemic encephalopathy with vegetable and animal protein diets. Dig Dis Sci 1982;27:1109-1116.
56. Greenbergcr NJ, Carley J, Schenkcr S, Bettingei I, Slamnes C, Beyei P: Effect of vegetable and animal protein diets in chronic hepatic encephalopathy. Dig Dis 1977:22:845- 855.
57. Bianchi GP, Marchesini G, Fabbri A, Rondclli A, Bugianesi E, Zoli M, Pisi E: Vegetable versus animal protein diet in cirrhotic patients with chronic encephalopathy. A randomized cross-over comparison. J Intern Med 1993:233:385-392.
58. Weber FL, Minco D, Frcsard KM, Banwell JG: Effects of vegetable diets on nitrogen metabolism in cirrhotic subjects. Gastroenterology 1985:89:538-544.